Agilent Announces Launch of Global Biomarker Pathologist Training Program
November 30 2020 - 08:00AM
Business Wire
Designed to enrich pathologists' skills in biomarker
interpretation and scoring techniques
Agilent Technologies Inc. (NYSE: A) today announced the launch
of the Biomarker Pathologist Training Program, a global initiative
created to empower pathologists to score biomarkers accurately and
confidently. Developed by Agilent – a worldwide leader in
developing and commercializing diagnostic products – this training
program incorporates Agilent’s unique expertise in companion
diagnostics and partnership with top pharmaceutical companies.
Biomarker testing has profoundly influenced the practice of both
pathology and oncology today. Targeted therapies have seen more
than 30% increase from 2019, and more than 50% of targeted
therapies currently in clinical trials are being co-developed with
a predictive biomarker [1][2]. The Agilent Biomarker Pathologist
Training Program will enable pathologists to gain confidence with
scoring methodologies to enable the pursuit of the right treatment
for patients.
"We are excited to successfully launch the Agilent Biomarker
Pathologist Training Program to further support our efforts in the
fight against cancer," said Simon Oestergaard, general manager and
vice president of Pathology at Agilent. "This program will allow
pathologists to learn and practice scoring techniques, to gain the
necessary confidence and competence to accurately score biomarker
cases in their own laboratories. Combined with Agilent’s
high-quality pathology staining solutions this training program
will help ensure pathologists can score cases with high
concordance."
The program, which will initially be available in Europe and
North America, followed by China and Asia, utilizes a digital
platform, Pathcore Scholar, where attendees can navigate both
standard and challenging cases. For Agilent products with approved
indications, the training, supports Agilent biomarkers only and
will provide strategies and best practices for delivering optimal
scoring results, which will in turn improve patient outcomes.
Training will be offered at different levels, from basic to
advanced, and both in-person and remotely, to address individual
training requirements.
For more information visit:
https://explore.agilent.com/biomarker-training-program
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics and applied chemical markets delivering
insight and innovation toward improving the quality of life.
Agilent instruments, software, services, solutions and people
provide trusted answers to customers' most challenging questions.
The company generated revenue of $5.34 billion in fiscal 2020 and
employs 16,400 people worldwide. Information about Agilent is
available at www.agilent.com. To
receive the latest Agilent news, subscribe to the Agilent
Newsroom. Follow Agilent on
LinkedIn, Twitter, and Facebook.
References:
- Targeted Cancer Therapies https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet
(accessed May 11, 2020)
- Badve, S.; Kumar, G. L., Eds. Predictive Biomarkers in
Oncology; Applications in Precision Medicine; Springer: Cham,
Switzerland, 2019
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201130005049/en/
Catherine Kaye Agilent Technologies +44 (0)7775 410632
Catherine.kaye@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Feb 2024 to Mar 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2023 to Mar 2024